Skip to main content

O614 Non-pneumatic anti-shock garment (NASG) reduces extreme adverse outcomes from obstetric hemorrhage and shock in Egyptian hospitals

Research Authors
S Miller, M Mourad-Youssif, M Fathalla, T Al-Hussaini, C Meyer, C Camlin, E Butrick, S Ismail
Research Journal
International Journal of Gynecology & Obstetrics
Research Rank
1
Research Year
2009

O641 Treatment with non-pneumatic anti-shock garment (NASG) improves outcomes for women with PPH/uterine atony in Egyptian referral facilities

Research Authors
M Mourad-Youssif, M Fathalla, T Al-Hussaini, H Martin, J Turan, R Mitchell, C Camlin, S Miller
Research Journal
International Journal of Gynecology & Obstetrics
Research Rank
1
Research Year
2009

O666 COST EFFECTIVENESS OF NON-PNEUMATIC ANTI-SHOCK GARMENT (NASG) FOR OBSTETRIC HEMORRHAGE

Research Authors
T Sutherland, J Downing, JG Kahn, DM Bishai, E Butrick, M Fathalla, MM Youssif, O Ojengbede, S Miller
Research Journal
International Journal of Gynecology & Obstetrics
Research Rank
1
Research Year
2012

Bone mineral density in women of a low socioeconomic level using DMPA for contraception in rural Upper Egypt

Research Authors
Mostafa Hussein, Dalia G Mahran, Osama A Farouk, Maher A El-Assal, Mohammad M Fathallah, Mahmoud S Romih
Research Journal
International Journal of Gynecology & Obstetrics
Research Rank
1
Research Year
2010

Non-pneumatic Anti-Shock Garments: Clinical Trials and Results

Research Authors
S Miller, JL Morris, MMF Fathalla, O Ojengbede, M Mourad-Youssif, P Hensleigh
Research Journal
International Federation of Obstetrics and Gynecology (FIGO) Book, Postpartum Hemorrhage: New Thoughts, New Approaches. UK: Sapiens Publications
Research Rank
1
Research Year
2012

Low molecular weight heparin (LMWH) for treatment of recurrent miscarriage negatively tested for anti phospholipid antibodies: a randomized controlled trial

Research Authors
SA Salman, OM Shaaban, KM Zahran, MM Fathalla, MA Anan
Research Journal
Fertility and Sterility
Research Rank
1
Research Year
2012

Vitamin D status in autism spectrum disorders and the efficacy of vitamin D supplementation in autistic children

Research Abstract
Objectives: Autism spectrum disorder (ASD) is a developmental disorder characterized by pervasive deficits in social interaction, impairment in verbal and nonverbal communication, and stereotyped patterns of interests and activities. Vitamin-D deficiency was previously reported in autistic children. However, the data on the relationship between vitamin D deficiency and the severity of autism are limited. Methods We performed a case-controlled cross-sectional analysis conducted on 122 ASD children, to assess their vitamin D status compared to controls and the relationship between vitamin D deficiency and the severity of autism. We also conducted an open trial of vitamin D supplementation in ASD children. Results Fifty-seven percent of the patients in the present study had vitamin D deficiency, and 30% had vitamin D insufficiency. The mean 25-OHD levels in patients with severe autism were significantly lower than those in patients with mild/moderate autism. Serum 25-OHD levels had significant negative correlations with Childhood Autism Rating Scale (CARS) scores. Of the ASD group, 106 patients with low-serum 25-OHD levels (30 ng/ml) participated in the open label trial. They received vitamin D3 (300 IU/kg/day not to exceed 5000 IU/day) for 3 months. Eighty-three subjects completed 3 months of daily vitamin D treatment. Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span. Conclusion Vitamin D is inexpensive, readily available and safe. It may have beneficial effects in ASD subjects, especially when the final serum level is more than 40 ng/ml. Trial registration number UMIN-CTR Study Design: trial Number: R000016846.
Research Authors
Khaled Saad, Abdel-Rahman AA, Elserogy YM, Al-Atram AA, Cannell JJ, Bjørklund G, Abdel-Reheim MK, Othman HA, El-Houfey AA, Hashem EA, Abd El-Aziz NH, Abd El-Baseer KA, Ahmed AE, Ali AM.
Research Journal
Nutritional Neuroscience
Research Rank
1
Research Website
http://www.maneyonline.com/loi/nns
Research Year
2015

Vitamin D status in autism spectrum disorders and the efficacy of vitamin D supplementation in autistic children

Research Abstract
Objectives: Autism spectrum disorder (ASD) is a developmental disorder characterized by pervasive deficits in social interaction, impairment in verbal and nonverbal communication, and stereotyped patterns of interests and activities. Vitamin-D deficiency was previously reported in autistic children. However, the data on the relationship between vitamin D deficiency and the severity of autism are limited. Methods We performed a case-controlled cross-sectional analysis conducted on 122 ASD children, to assess their vitamin D status compared to controls and the relationship between vitamin D deficiency and the severity of autism. We also conducted an open trial of vitamin D supplementation in ASD children. Results Fifty-seven percent of the patients in the present study had vitamin D deficiency, and 30% had vitamin D insufficiency. The mean 25-OHD levels in patients with severe autism were significantly lower than those in patients with mild/moderate autism. Serum 25-OHD levels had significant negative correlations with Childhood Autism Rating Scale (CARS) scores. Of the ASD group, 106 patients with low-serum 25-OHD levels (30 ng/ml) participated in the open label trial. They received vitamin D3 (300 IU/kg/day not to exceed 5000 IU/day) for 3 months. Eighty-three subjects completed 3 months of daily vitamin D treatment. Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span. Conclusion Vitamin D is inexpensive, readily available and safe. It may have beneficial effects in ASD subjects, especially when the final serum level is more than 40 ng/ml. Trial registration number UMIN-CTR Study Design: trial Number: R000016846.
Research Authors
Khaled Saad, Abdel-Rahman AA, Elserogy YM, Al-Atram AA, Cannell JJ, Bjørklund G, Abdel-Reheim MK, Othman HA, El-Houfey AA, Hashem EA, Abd El-Aziz NH, Abd El-Baseer KA, Ahmed AE, Ali AM.
Research Journal
Nutritional Neuroscience
Research Rank
1
Research Website
http://www.maneyonline.com/loi/nns
Research Year
2015

Vitamin D status in autism spectrum disorders and the efficacy of vitamin D supplementation in autistic children

Research Abstract
Objectives: Autism spectrum disorder (ASD) is a developmental disorder characterized by pervasive deficits in social interaction, impairment in verbal and nonverbal communication, and stereotyped patterns of interests and activities. Vitamin-D deficiency was previously reported in autistic children. However, the data on the relationship between vitamin D deficiency and the severity of autism are limited. Methods We performed a case-controlled cross-sectional analysis conducted on 122 ASD children, to assess their vitamin D status compared to controls and the relationship between vitamin D deficiency and the severity of autism. We also conducted an open trial of vitamin D supplementation in ASD children. Results Fifty-seven percent of the patients in the present study had vitamin D deficiency, and 30% had vitamin D insufficiency. The mean 25-OHD levels in patients with severe autism were significantly lower than those in patients with mild/moderate autism. Serum 25-OHD levels had significant negative correlations with Childhood Autism Rating Scale (CARS) scores. Of the ASD group, 106 patients with low-serum 25-OHD levels (30 ng/ml) participated in the open label trial. They received vitamin D3 (300 IU/kg/day not to exceed 5000 IU/day) for 3 months. Eighty-three subjects completed 3 months of daily vitamin D treatment. Collectively, 80.72% (67/83) of subjects who received vitamin D3 treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span. Conclusion Vitamin D is inexpensive, readily available and safe. It may have beneficial effects in ASD subjects, especially when the final serum level is more than 40 ng/ml. Trial registration number UMIN-CTR Study Design: trial Number: R000016846.
Research Authors
Khaled Saad, Abdel-Rahman AA, Elserogy YM, Al-Atram AA, Cannell JJ, Bjørklund G, Abdel-Reheim MK, Othman HA, El-Houfey AA, Hashem EA, Abd El-Aziz NH, Abd El-Baseer KA, Ahmed AE, Ali AM.
Research Department
Research Journal
Nutritional Neuroscience
Research Member
Research Rank
1
Research Website
http://www.maneyonline.com/loi/nns
Research Year
2015
Subscribe to